Try our Advanced Search for more refined results

JAZZ PHARMACEUTICALS, INC. v. AMNEAL PHARMACEUTICALS, LLC

  1. May 13, 2016

    Jazz Makes Deal In Xyrem IP Fight With Ranbaxy, Sun, Ohm

    Jazz Pharmaceuticals Inc. has agreed to drop its claims against generic-drug makers Ranbaxy, Sun and Ohm in a patent infringement case involving the narcolepsy drug Xyrem after the companies resolved their differences and struck a licensing agreement, the company told a New Jersey federal judge Thursday.

  2. January 22, 2016

    Judge Threatens 'Severe' Sanctions In Xyrem IP Fight

    A New Jersey federal magistrate judge concluded Friday that generic drugmakers Par Pharmaceutical Inc. and Amneal Pharmaceutical LLC "unequivocally" violated a court order when their attorneys made reference to confidential inter partes review documents during related patent litigation over the narcolepsy drug Xyrem.

  3. January 15, 2016

    Jazz's Xyrem Patent Cases Consolidated In NJ Fed Court

    A New Jersey federal judge has ordered the consolidation of several infringement cases brought by Jazz Pharmaceuticals against other drug companies regarding its patents for Xyrem, a narcolepsy drug the company has attempted to block generic manufacturers from producing for years.

  4. June 25, 2014

    Drug Challenged Under AIA Biz Method Review For 1st Time

    Amneal Pharmaceuticals LLC and others asked the Patent Trial and Appeal Board on Tuesday to invalidate a patent for distribution of Jazz Pharmaceuticals Inc.'s narcolepsy drug Xyrem as an abstract idea, the first time the America Invents Act's business method review program has been used in a drug case.